Roth Capital lowered the firm’s price target on Revelation Biosciences (REVB) to $16 from $20 but keeps a Buy rating on the shares. The company ended 2025 with pro forma cash of $17.3M, enough funding into Q1 of 2027, the analyst tells investors in a research note. The firm further cites the Gemini trial safety data, which was well-tolerated at the target dose with all adverse events reported as mild at that dose and including transient headache, chills, loose stool, and body aches.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REVB:
- Revelation Biosciences files to sell 4.27M shares of common stock for holders
- Revelation Biosciences Raises Capital via Warrant Inducement
- Revelation Biosciences Inc trading halted, news pending
- Revelation Biosciences announces 1-for-4 reverse stock split
- Revelation reaches agreement with FDA on Gemini approval pathway